UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease

UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease — Blankdot

Command Palette